Biogen says it will up Samsung Bioepis cut
Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.
You may also be interested in...
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.
Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.